The partnership will select the most promising therapeutic targets and drugs from the respective organisations’ portfolios with the aim of developing them through to the end of Phase II trials in a bid to maximise licensing value.
The group will also seek to secure federal funding for the development work based on currently available research data.
The contract research and manufacturing services (CRAMS) firm said, "This novel academic and industrial collaboration demonstrates our commitment to partner with globally renowned academia in order to identify and deliver affordable innovation and healthcare solutions to the patients worldwide.”